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INTRODUCTION
Polycystic  ovary  syndrome  (PCOS)  is  the  most  frequent  androgen 
disorder in women. A prevalence of 5% - 10% of PCOS was found in women 
of  reproductive  age.  These  patients  have  a  tendency  to  abdominal  fat 
accumulation and over weight which is partly associated with over production 
of ovarian androgens. The increased insulin levels has been attributed to insulin 
resistance which has been suggested as the principle underlying disorder of 
PCOS.  Insulin  resistance  is  defined  as  a  decreased  biological  response  to 
normal levels of circulating insulin and is found in obese non diabetic people, 
type  2  diabetes  and  those  women  with  polycystic  ovarian  syndrome.  The 
percentage of PCOS women with insulin resistance was found to vary in the 
results given by different workers in this field. As per their work in western 
population it varied from 60% to 80%. The varying high percentage obtained 
by  previous  workers  created  the  interest  and  hence  this  work  on  insulin 
resistance  in  PCOS  has  been  selected  with  the  view  of  determining  the 
percentage of PCOS with insulin resistance in our population. 
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REVIEW OF LITERATURE
 Polycystic  ovary  syndrome  is  a  common  condition  characterised  by 
menstrual  abnormalities  and  clinical  or  biochemical  features  of  hyper 
androgenism1.  Interest  in  polycystic  ovary  syndrome has  increased  recently 
with  the  realization  that  this  syndrome  involves  multisystem effects  which 
includes organs other than the reproductive system. Initially called the stein - 
leventhal  syndrome  in  1930s,  PCOS  is  now  recognised  to  be  a  metabolic 
syndrome  which  may  include  hyperinsulinemia,  hyperlipidemia,  diabetes 
mellitus  and  possibly  cardiac  disease,  and  also  the  more  conventionally 
recognised  increase  in  androgen  levels,  cosmetic  problems,  anovulation, 
infertility, endometrial cancer and obesity2,3.
INCIDENCE
The percentage of PCOS in women of child bearing age was found to be 
5 - 10% as per Robert J. Norman et al.,  who have based their study on the 
diagnostic criteria of US National institute of Health.  Moreover as per their 
study  the  percentage  of  PCOS  increased  to  30%  in  women  who  are 
infertile4,5,13.
PCOS is a life long condition and its effects are found to manifest at all 
ages.  Depending on the age group the manifestations are premature puberty 
during  childhood,  hirsuitism  and  menstrual  abnormalities  during  teenage, 
infertility and glucose intolerance during early adulthood and middle life and 
diabetes mellitus and cardiovascular disease in later life. The causes for the 
above manifestations are tabulated in Chart No.11.
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CHART NO.1
MANIFESTATIONS OF PCOS AT DIFFERENT AGES1
Inutero Peripuberty
Adolescence & 
adulthood
Ageing
Small baby 
syndrome
Exaggerated 
adrenarche
PCOS Metabolic syndrome
Intrauterine 
growth 
retardation
Increased levels of 
  * Adrenal androgens 
  * Insulin
- Functional ovarian 
   hyperandrogenism
- Anovulation
 - Hyperandrogenism
-  Polycystic ovaries 
- Obesity (50%)
- Diabetes
- Hypertension
- Dyslipidaemia 
- Increased 
    plasminogen 
  activator inhibitor-1
Leads to long 
term health 
defects
Leads to precocious 
puberty
Leads to 
reproductive 
disorder
Leads to metabolic 
effects
PATHOGENESIS
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Pathogenesis of PCOS is poorly understood, but the primary defect may 
be insulin resistance, androgen excess and abnormal gonadotropin dynamics6. 
Recent  evidence  suggests  that  the  principal  underlying  disorder  is  one  of 
insulin resistance, with resulting hyperinsulinemia stimulating excess ovarian 
androgen production7,8.  There  is  a  failure  to  ovulate,  the  follicles  becoming 
cystic  and  shows  hyperplasia  of  theca  interna.  It  is  supposed  that  the 
hyperthecosis  is  related  to  an  overproduction  of  androgens  which  reduces 
granulosa cell proliferation and maturation as well as stimulating fibrosis of 
surrounding  stroma  and  capsule.  Though  there  are  no  specific  histological 
features which charaterize the ovary in PCOS, follicular as well as theca lutein 
cyst may be present.  Moreover ripening follicles  and occasionally an active 
corpus  luteum  can  be  found.  This  shows  that  ovulation  may  occur 
intermittently despite thick capsule.
Irrespective of microscopic appearances, it is clearly seen that there is no 
defect in the hypothalamic - pituitary - ovarian axis. However, normal function 
is masked by inhibition of ovarian follicular development and in appropriate 
feedback  to  the  pituitary.  The  high  estrogen  production  is  largely  due  to 
conversion of androgens to estrogen in the ovary and peripherally. This causes 
an  increase  in  Luteinizing  hormone  (LH)  and  a  decrease  in  follicular 
stimualting hormone (FSH). A vicious circle is established that the increase in 
LH induces thecal hyperplasia and increased androgen synthesis in ovary.
High levels of androgen result in the peripheral production of estrogen 
and reduction in sex hormone - binding globulin. This leads to an increased 
level of free androgens to produce hirsuitism and to be converted to estrogen9. 
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The elevated androgens contribute to the morphologic effect within the ovary 
preventing normal follicular development and inducing premature atresia. In 
another aspect of vicious cycle, the local androgen block is a major obstacle 
that  maintains  the  steady  state  of  persistent  anovulation.  When  ovarian 
androgen  concentrations  are  high  they  can  be  converted  to  5α  -  reduced 
metabolites which inhibit aromatase activity and estrogen production10.
Following wedge resection of ovaries the androgen level is reduced and 
ovulatory cycles return. This shows that the intraovarian androgen effect is a 
principal  factor  in  preventing  normal  cycling11.  In  this  manner  the  classic 
picture of polycystic ovary is attained, displaying numerous follicles in early 
stages of development and atresia and dense stromal tissue. Thus the polycystic 
ovary is the result of "vicious cycle", which can be initiated at any one of many 
entry  points.  Altered  function  at  any  point  in  the  cycle  leads  to  polycystic 
ovary.
MORPHOLOGY
The polycystic ovary is usually enlarged and characterised by a smooth 
pearly white capsule.  The surface area is doubled and this gives an increase of 
2.8 times the average volume. Same number of primordial follicles are present, 
but the number of growing and atretic follicles is doubled. Each ovary may 
contain 20 - 100 cystic follicles.   Thickness of tunica is increased by 50%. 
There is increase in cortical stromal thickness. On cut section it shows cystic 
follicles and hyperplasia of theca interna12. The gross appearance of polycystic 
ovary is shown in Fig.1 and 2.
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CLINICAL FEATURES
In  many women the  symptoms are  easily  recognizable,  but  ethnicity 
influences the extent of symptoms. The national institute of child health and 
development  held  a  consensus  meeting  to  develop  the  following diagnostic 
criteria for PCOS.
1. Clinical or biochemical evidence of hyperandrogenism.
2. Menstrual irregularity due to oligo ovulation or anovulation.
3. Exclusion of other known disorders such as congenital adrenal 
hyperplasia or hyperprolactinemia.
Hyperandrogenism : The wide spectrum of manifestations ranges from 
mild acne and increased terminal (coarse) hair growth on midline structures 
(Face, Neck, Abdomen) to android changes in body habitus with waist-to-hip 
ratios of more than one. In addition non hirsute women with anovulation may 
have laboratory evidence of hyperandrogenism.
Frank or rapid virilization including clitoromegaly, vocalcord thickening 
or male pattern baldness are rare in PCOS but when present suggests  another 
cause  of  hyperandrogenesim  like  adrenal  disorders  or  androgen  producing 
tumors.
Menstrual irregularity  :  Manifest as oligo ovulation or anovulation 
and present as oligomenorrhoea or amenorrhoea.  Among women with more 
regular menses many have variable degrees of ovulatory  dysfunction. Often 
the  normal  menstrual  flow of  3  -  5  days  /  28 -  35 days  occurs  at  first  on 
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attaining  menarche  but  becomes  less  frequent  after  a  period  of  2  years 
occurring once during 45 to 365 days14.  Because the estrogen from ovarian and 
adipose tissue stimulates proliferation of endometrium that is not stabilized by 
post  ovulatory  progesterone,  bleeding  can  be  unpredictable,  heavy,  and 
prolonged.
SUGGESTED DIAGNOSTIC CRITERIA FOR PCOS15
1. Clinical Features
- Amenorrhoea,  oligomenorrhoea  or  dysfunctional  uterine 
bleeding
- Anovulatory infertility
- Hirsutism and / or acne
- Central obesity
2. Endocrine Abnormalities on Laboratory Tests
- Elevated androgen (testosterone levels)
- Elevated LH concentration with normal to mildly elevated 
FSH level
- Insulin resistance with hyperinsulinemia.
3. Radiologic abnormalities on USG examination
- Multiple (nine or more) subcortical follicular cysts
- Increased ovarian stromal density and / or volume
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4. Exclusion of other etiologies
- Prolactinoma 
- Virilizing tumours of adrenal or ovarian tumors
- Congenital adrenal hyperplasia
- Cushing's syndrome
The diagnosis is based on the presence of some or all of the common 
clinical  features  and  is  confirmed  by  the  presence  of  biochemical  or 
radiological  evidence  of  endocrine  abnormality  and  exclusion  of  other 
etiologies15.
According to Marilyn R. Richardson the evaluation should follow these 
principles. 
1. Detect hyperandrogenism
2. Exclude other causes of hyper androgenesim
3. Exclude  other  etiologies  of  amenorrhoea  and  to  confirm  by 
Laboratory investigations which are tabulated in Chart - 214.
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CHART - 2
LABORATORY INVESTIGATION OF PCOS14
Test Normal value Purpose
b-hCG < 5 mlU per mL (<5 lU per L) Exclude pregnancy
TSH 0.5 to 4.5 μU per mL (0.5 to 4.5 mU 
per L)
Exclude thyroid 
dysfunction
Prolactin < 20 ng per mL (<20 μg per L) Exclude 
hyperprolactinemia
Testosterone 
(total)
< 20 ng per mL (<0.7nmol per L) Exclude androgen - 
secreting neoplasm
Testosterone 
(free)
20 to 30 years - 0.06 to 2.57 pg per 
mL (0.20 to 8.90 pmol per L)
40 to 59 years - 0.4 to 2.03 pg per 
mL (1.40 to 7.00 pmol per L)
Establish diagnosis or 
monitor therapy
DHEAS 600 to 3,400 ng per mL (1.6 to 9.2 
μmol per L)
Exclude androgen - 
secreting neoplasm
Androstenedione 0.4 to 2.7 ng per mL (1.4 to 9.4 
nmol per L)
Establish diagnosis
17a- 
hydroxyprogester
one 
Follicular phase <2 μg per L (6.1 
nmol per L)
Establish - Non classical 
Adrenal hyperplasia 
(NCAH)
Fasting insulin < 20 μU per mL (<144 pmol per L) Exclude 
hyperinsulinemia
Fasting glucose 65 to 119 mg per dL (3.6 to 6.6 
mmol per L)
Exclude type 2 diabetes 
or glucose intolerance
Fasting glucose : 
insulin ratio
> = 4.5 Exclude insulin 
resistance
Cholesterol (total) 150 to 200 mg per dL (1.5 to 2 g per 
L)
Monitor lifestyle changes
HDL cholesterol 35 to 85 mg per dL (0.9 to 2.2 mmol 
per L)
Monitor lifestyle changes
LDL cholesterol 80 to 130 mg per dL (2.1 to 3.4 
mmol per L)
Monitor lifestyle changes
Endometrial 
biopsy
Negative for hyperplasia / 
malignancy
Exclude malignancy or 
hyperplasia
INSULIN  RESISTANCE
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Insulin resistance refers to the clinical condition in which the biologic 
response  to  insulin  is  diminished  to  below  normal  levels16.  The  decreased 
response can be the result of 2 states namely of either decreased sensitivity to 
insulin or decreased responsiveness to insulin or a combination of both.
Decreased Sensitivity to insulin :  There is a rightward shift  in dose 
response to the hormone but the maximal response remains normal.
Decreased Responsiveness to insulin : The dose response is normal but 
the maximal response is decreased.
The two states of insulin resistance are depicted as a graph in Fig.No.317. 
From  molecular  perspective  insulin  resistance  can  occur  at  multiple 
levels which can be prereceptor, receptor or post receptor levels.
LEVELS OF INSULIN RESISTANCE
1. Pre receptor insulin resistance
This is rare today but formerly shown by patients with high levels of 
circulating antibodies to insulin. These antibodies blocked the binding of ligand 
to its receptor18.
2. Insulin resistance at the level of receptor
This may be due to genetic alterations in :
a. Receptor expression or structure (The normal structure is 
elaborated in Fig.No.4).
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b. Secondary  changes  in  receptor  activity  due  to  serine 
phosphorylation.
c. Down regulation of receptor concentration.
3. Insulin resistance at post receptor level
This can occur any where on one of the common or branches pathways 
of insulin signaling.
In most common states of insulin resistance the defects are at multiple 
levels. For example in type 2 diabetes insulin resistance is associated with a 
decrease of the following :
- receptor concentration
- receptor kinase activity
- concentration and phosphorylation of insulin receptor substrates 
(IRS-I and IRS-2)
- phosphatidyl ionositol (PI)-3 kinase activity
- glucose transport translocation and 
- defects in activity of intracellular enzymes19,20.
Insulin resistance can either be due to genetic causes or acquired causes.
Insulin resistance due to genetic defects in insulin receptor expression or 
sequences  is  relatively  rare.  This  occurs  in  most  severe  forms  of  insulin 
resistance.  In  humans they may present as  different  disease syndromes like 
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Leprechaunism, Rabson Mendenhall Syndrome and type A syndrome of insulin 
resistance. Though there is some correlation between the severity of the genetic 
defect  in receptor  function and the  severity  of the clinical  presentation,  the 
correlation is relatively weak, indicating that other genetic or acquired factors 
can modify the insulin resistant state significantly21.
ACQUIRED FORM OF INSULIN RESISTANCE
This occurs due to multiple mechanisms which are illustrated in Fig.5 
and are enumerated below :
1. Insulin receptor down regulation22,23 
In this condition there is mild hyper insulinemia due to tissue resistance, 
which results in internalization and increase in degradation of insulin receptors. 
This occurs in obesity and type 2 diabetes.
2. Down regulation in insulin receptor substrates24,25,27
Hyperinsulinemia can lead to down regulation of IRS producing greater 
decrease  in  insulin  signaling.  In  humans,  the  levels  of  insulin  receptor  and 
insulin receptor substrate - I in some tissues can be reduced by more than 50% 
in some of these insulin resistant states.
3. Increase  serine  phosporylation  of  receptor  and  its 
substrates26,28,29
This leads to decreased kinase activity  of the receptor  and decreased 
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tyrosine  phosphorylation  of  the  receptor  substrates  by  protein  tyrosine 
phosphatases  (PTPase).  Serine  phosphorylation  is  caused  by  several  serine 
kinases, like protein kinase C (PKC), proteinkinase B (PKB), mitogen activated 
protein kinases (MAP).
The upstream stimulators of these serine kinases are also multiple. For 
example in obesity and type 2 diabetes there is increased level of circulating 
free fatty acids while in obesity tumor necrosis factor α (TNF α), leptin and 
other  peptides are  made and released from adipose  tissue.  Another  class  of 
proteins act as inhibitors of insulin signaling. They are suppressor of cytokines 
signalling  (SOCS)  proteins.  These  proteins  interact  with  phosphorylated 
receptor and block insulin action30,31,32. These play a role in insulin resistance in 
stress induced states like bacterial infection and type II diabetes.
Clinical  Manifestations of genetic  conditions of insulin resistance are 
hyperinsulinemia, dyslipidemia, hyper-tension and impaired glucose tolerance 
or  insulin  resistant  diabetes33.  Acanthosis  nigricans  is  a  characteristic  skin 
lesion in insulin resistance consisting of velvety and papillomatous pigmented 
hyperkeratosis of flexuses and neck34. In women extreme insulin resistance is 
also  associated  with  hyperandrogenism,  hirsuitism,  menstrual  abnormalities 
and polycystic ovary disease. 
Though  several  factors  contribute  to  insulin  resistance,  genetic 
inheritance, obesity and environment which include a variety of factors like 
hormones, increased nutrient availability and age play a very important role in 
19
its pathogenesis, which is illustrated below :
GENETIC
Defects in both insulin action and insulin secretion are present in type 2 
diabetes  and  both  are  believed  to  be  genetically  predetermined.  A  strong 
genetic  basis  for  insulin  resistance  is  suggested  by  the  high  prevalence  in 
certain populations.  To date several rare mutations or genes associated with 
insulin action have been linked to extreme insulin resistance. Though these are 
all  rare  conditions,  their  study  has  been  helpful  in  elucidating  the  general 
pathophysiology  of  insulin  resistance.  Severe  insulin  resistance  has  been 
reported in conjunction with more than 100 naturally occurring mutations in 
the  insulin  receptor  gene,  as  well  as  in  the  complete  absence  of  insulin 
receptors35,36,37.  The  varying  severity  and diversity  of  their  phenotypes  have 
resulted in the description of several clinical syndromes like leprechaunism, 
Rabson - Mendenhall syndrome, and Type A insulin resistance.
OBESITY 
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Genetic
Environmen
t
Obesity
Insulin 
Resistance
The quantity of body fat varies widely in mammals ranging from 2% to 
50% of body mass. This large variation in fat mass is apparently determined 
both  by  an  individual's  genetic  background  and  by  environmental  factors, 
including diet and physical activity. Excess body fat, or obesity, is an important 
factor in the pathogenesis of insulin resistance, and substantially increase the 
risk  of  type  2  diabetes38,39,40.  While  adipose  tissue  influences  whole-body 
insulin  action  both  through  release  of  free  fatty  acids  and  by  secretion  of 
adipose  derived  proteins.  They include both pro-inflammatory  peptides  like 
tumor necrosis factor α (TNF α), interleukin - 6 (IL-6), transforming growth 
factor β, C - reactive protein, monocyte chemotactic protein - 1 (MCP-1) and 
newly identified hormones like adiponectin, leptin and resistin82,83. Decreased 
circulating levels of adiponectin and defective leptin action accompany obesity 
and  insulin  resistance.  Adipose  -  derived  proinflammatory  moleceules  are 
believed to induce systemic insulin resistance. In obesity the levels of these 
circulating adipokines are increased17. TNF - α leads to insulin resistance by 
increasing serine phosphorylation of IRS-I and decreasing insulin -  receptor 
kinase activity41.
ENVIRONMENT
This refers to variety of factors including hormones, increased nutrient 
availability  and  age.  Hyperinsulinemia  is  the  classic  indicator  of  insulin 
resistance and may itself contribute to insulin resistance in type 2 diabetes and 
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obesity.  Growth  hormone  acts  at  several  levels  to  block  insulin  action 
contributing to insulin resistance including the inhibition of phosphorylation of 
the insulin receptor and IRS-I in response to insulin administration42. Increased 
nutrient intake like increased glucose and free fatty acids also causes insulin 
resistance. Final environment factor is advancing age which also contribute to 
insulin resistance. The features of aging like increased fat  mass particularly 
increased viseral obesity, increased circulating levels of inflammatory proteins, 
and  increased  cellular  accumulation  of  triglycerides  contribute  to  insulin 
resistance43,44. 
Insulin  resistance  occurs  both  in  physiologic  states  and  disease 
conditions which are enumerated below : 
Physiologic conditions
- Puberty
- Pregnancy
Disease states
- Type 2 diabetes
- Obesity
- Hypertension
- Polycystic ovarian disease
- Variety  of  genetic  syndromes  which  are  classified  as  genetic 
defects  in  insulin  receptor,  immunologic  mechanisms  and 
disorders of unknown etiology and are tabulated in Chart No.3.
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Insulin resistance is also present in many states of stress, in association 
with infection and secondary to treatment with variety of drugs, particularly 
glucocorticoids19.
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CHART NO. 3
GENETIC SYNDROMES WITH SEVERE INSULIN RESISTANCE16
Genetic defects in insulin receptor
- Type A syndrome
- Rabson mendenhall syndrome
- Leprechaunism
Immunologic, autoimmune
- Antibodies to insulin receptor
Type B syndrome
Ataxia - telangiectasia
- Antibodies to insulin
Disorders of unknown etiology : Lipotrophic diabetes
Congenital-Dominant inheritance (Kobberling - Dunningan Syndrome)
      - Autosomal recessive inheritance (Seip Syndrome)
Acquired - Generalised (Lawrence Syndrome) 
     - Partial lipoatrophy
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INVESTIGATIONS FOR EVALUATION OF INSULIN RESISTANCE
1. Fasting Insulin Levels
Fasting serum insulin level greater than the upperlimit of normal for the 
assay  used  is  considered  evidence  of  insulin  resistance.  With  normally 
functioning pancreatic β cells, fasting and peak plasma insulin concentration 
are directly related to the degree of peripheral insulin resistance as elaborated 
below.
1. Fasting plasma insulin 2 to 25 μu/ml is the reference range for 
insulin.
2. Fasting plasma insulin 25 to 50 μu/ml - mild to moderate insulin 
resistance and rarely exceeds 50 μu/ml.
3. Fasting plasma insulin close to normal or markedly elevated 200 
- 400 μu/ml in extreme insulin resistance16. 
2. Oral Glucose Tolerance testing (OGTT)
During this test a fasted patient takes 75 gm oral dose of glucose and 
blood glucose levels are measured over the following 2 hours. This may be 
used to diagnose diabetes mellitus. This can be normal or mildly abnormal in 
simple insulin resistance.
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3. Hyperinsulinemic euglycemic clamp
The gold standard for investigating and quantifying insulin resistance is 
the "hyperinsulinemic euglycemic clamp". It is so called because it measures 
the amount of glucose necessary to compensate for an increased insulin level 
without  causing  hypoglycemia.  With  this  technique  insulin  is  infused  in 
gradually increasing amounts, along with administration of glucose to prevent 
fall  in plasma glucose. The steady -  rate of peripheral glucose utilization at 
several insulin levels is measured as milligrams of glucose used per kg of body 
weight  per  minute.  The  values  provide  an  estimation  of  the  sensitivity  of 
peripheral  tissues  to  exogenous insulin  administration.  This  is  performed at 
specialized medical centres and not  required for clinical evaluation16.
Other atlernative methods of evaluation of insulin resistance are glucose 
to insulin ratio and homeostatic model assessment45.
A  fasting  glucose  to  insulin  ratio  is  a  useful  measure  of  insulin 
sensitivity and according to studies it provided the best single fasting measure 
of insulin action and was comparable with glucose stimulated parameters.  A 
fasting G/I ratio <4.5 has significant correlation with insulin resistance and has 
been studied for use as a screening test in PCOS14. 
The homeostatic model assessment value for insulin resistance (HOMA 
IR) is calculated as follows :
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HOMA IR = [(Glucose in mg / dl x 0.05551) x insulin in micro units / 
ml] / 22.5.
Glucose and insulin are fasting plasma values. Glucose in the formula is 
mmol/l (mg/dl x 0.05551) and insulin is in micro units / ml46. HOMA IR levels 
>3.8 is indicative of insulin resistance as per Dr.Elizabeth G. Nabel89. 
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INSULIN RESISTANCE IN PCOS
The  association  between  a  disorder  of  carbohydrate  metabolism  and 
androgen excess was first described in 1921 by Archard and Thiers80.  and was 
called the "diabetes of bearded women". Since then the association between 
PCOS  and  insulin  resistance  or  impaired  glucose  tolerance  has  been  well 
recognised47.  Insulin  resistance  accompanied  by  compensatory 
hyperinsulinemia is recognised as the most significant metabolic aberration in 
polycystic ovary syndrome46. It  has become increasingly evident that insulin 
resistance plays a significant role both as a cause and result of the syndrome48.
The  resistance  to  the  action  of  insulin  in  PCOS  primarily  refers  to 
impaired  action  of  this  hormone  on  glucose  transport  and  antilipolysis  on 
adipocytes  in  the  presence  of  normal  insulin  binding49-51.  In  turn  the 
compensatory  hyperinsulinemia leads  to  an  exaggerated  effect  of  insulin  in 
other  less  traditionally  responsive  tissues  including  stimulated  androgen 
secretion by the ovarian theca cells52,53. The insulin resistance which underlies 
the androgenic features of the disorder is highlighted by the observation that 
the  administration  of  insulin  sensitizing  agents  is  associated  with  an 
improvement  in  clinical,  endocrinologic  and  metabolic  features  in  many 
patients with PCOS 54-57.
The state of insulin resistance in PCOS is though not well understood it 
can be due to :
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1. Peripheral  target  tissue  resistance  to  insulin  which  can  be  the 
result of autoantibodies to insulin receptors leading to decraese in 
insulin binding; Post receptors defects59. 
2. Decreased hepatic clearance of insulin due to decreased hepatic 
extraction60.
Current research has focused on identifying a genetic predisposition for 
insulin  resistance in this syndrome48.
In order to understand the molecular defect underlying insulin resistance 
in  PCOS,  Dunaif  and  co-workers58,47 studied  the  differences  between  skin 
fibroblasts  from  women  with  and  without  PCOS  with  respect  to  insulin 
dependent signal transduction. The fibroblasts of women with PCOS showed 
no change in insulin binding or receptor affinity59. In fibroblasts the mitogenic 
pathway of insulin action is intact and this is consistent with a selective defect 
in insulin signaling. While in PCOS the skeletal muscle is resistant to insulin in 
vivo, cultured muscle cells have normal insulin sensitivity, consistent with a 
major role of extrinsic factors in producing insulin resistance in the tissue58. 
However a post receptor defect was observed. This defect is characterized by 
increased basal insulin receptor serine phosphorylation and there is decreased 
in insulin dependent tyrosine phosphorylation of  the insulin receptor.  These 
abnormal  patterns  of  phosphorylation  of  specific  residues  of  the  insulin 
receptor  might  represent a  molecular mechanism responsible for  the  insulin 
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resistance, anovulation and androgen excess in PCOS.
The androgen excess  and insulin  resistance are  often associated with 
acanthosis nigricans which is a grey brown velvety discolouration around skin 
of neck, groin and axillae and is a marker for insulin resistance. The presence 
of  acanthosis  nigricans  in  hyperandrogenic  women  is  dependent  on  the 
presence and severity of insulin resistance and hyperinsulinemia. But it is not 
specific  for  insulin  resistance  as  it  can  be  seen  in  the  absence  of  insulin 
resistance or androgen excess.
Insulin resistance is frequently  observed in both non obese and obese 
women with  PCOS59.  In  studies  that  were  performed to  determine  whether 
insulin resistance occurred in patients with PCOS in the absence of obesity and 
acanthosis nigricans, significant degree of insulin resistance was found to exist 
in  non  obese  patients  with  PCOS  in  whom  the  insulin  resistance  was 
significantly  related  to  LH  and  free  testosterone  concentration60.  Insulin 
resistance observed in the absence of overweight can be secondary to a defect 
in  the  insulin  transduction  pathway  mainly  by  a  defect  in  receptor 
phosphorylation.  This  enhances  hyperandrogenism  by  increasing  ovarian 
androgen production61. More severe degrees of insulin resistance or impaired 
glucose tolerance are more common in obese women with PCOS47.  In such 
patients  obesity  perse  is  the  cause  of  insulin  resistance60.  In  coexistance of 
obesity  and  insulin  resistance  in  PCOS,  there  is  excess  cardivoascular  risk 
which is contributed by obesity.  Most of these obese patients exhibit higher 
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body mass index,  androgen level and TGL levels  and decrease in HDL - c 
levels. Insulin resistance was the main determinant of HDL - c and TGL levels 
in PCOS62. Hence measures to decrease insulin resistance must be considered 
earlier to minimise the potential risk of developing diabetes and coronary artery 
disease at later ages of life in these patients.
The clinical presentation of insulin resistance depends on the ability of 
pancreas  to  compensate  for  target  tissue  resistance.  When  compensation  is 
effective  it  leads  to  hyperinsulinemia59.  Evidence  for  hyperinsulinemia 
contributing to the androgen excess by stimulating the theca cells is strong63. 
The existence of stimulatory action of insulin on LH - secretion will help to 
explain  the  elevated  LH concentration  in  this  syndrome.  Another  action  of 
insulin  is  to  decrease  the  sex  hormone  binding  globulin  synthesis  in  liver 
thereby  leading  to  an  increase  in  free  androgen  concentration64.  Further 
hyperinsulinemia  potentiates  adrenal  androgen  secretion  by  ACTH 
stimulation65.  It  contributes  to  increased  risk  of  cardiovascular  disease  by 
means of direct atherogenic action and indirectly affecting of lipoprotein (LP) 
profile12. Hyperinsulinemia may be important factor in the infertility associated 
with PCOS65. Hyperinsulinemia therefore is a key component of PCOS. 
12There  are  studies  indicating  that  androgens  can  induce 
hyperinsulinemia. However most of the evidence supports hyperinsulinemia as 
a primary factor, especially the experiments in which turning off the ovary with 
a  Gonadotropin  releasing  hormone  (GnRH)  agonist  does  not  change  the 
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hyperinsulinemia or insulin resistance.  This  indicates that  disordered insulin 
action precedes the increase in androgens. Indeed  there are many reasons to 
believe that hyperinsulinism causes hyperandrogenism which are enumerated 
below.
1. Administration  of  insulin  to  women  with  polycytic  ovaries 
increases circulating androgen levels66.
2. Administration of glucose to hyperandrogenic women increases 
the circulating levels of both insulin and androgens67.
3. Weight loss decreases the levels of both insulin and androgens 
and  increases  the  levels  of  insulin  like  growth  factor  binding 
protein68.
4. In vitro insulin stimulates theca cell androgen production69,70.
5. The experimental reduction of insulin levels in women reduces 
androgen  levels  in  women  with  polycystic  ovaries  but  not  in 
normal women71-73.
6. After normalization of androgens with GnRH agonist treatment 
the  hyperinsulinemia  response  to  glucose  tolerance  testing 
remains abnormal in obese women with polycystic ovaries74-75. 
7. Correlation  of  hyperandrogenism  with  oral  contraceptive 
treatment,  surgical  wedge  resection  or  laproscopic  ovarian 
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cautery does not restore insulin resistance and abnormal lipid and 
lipoprotein levels to normal76. 
Measures of insulin resistance in PCOS included fasting serum insulin, 
glucose to insulin ratio and homeostasis model assessment (HOMA)45.  These 
women  also  exhibit  elevated  levels  of  C  reactive  protein  and  endothelium 
dysfunction which are directly correlated with insulin resistance77.
A prospective case control study was done to determine the prevalence 
of  insulin  resistance in patients  with PCOS. Compared with PCOS patients 
without insulin resistance, patients with insulin resistance were more obese and 
had  high  beta  cell  function.  The  prevalence  of  insulin  resistance  was  64% 
according  to  HOMA  -  IR  measurement78.  Although  insulin  resistance  is  a 
common abnormality in PCOS it doesn't seem to be an universal feature78. In 
PCOS insulin resistance was diagnosed in 65.4% using glucose insulin ratios. 
In obese women (body mass index >28 in 48% of group). IR was present in 
76.7% as measured by glucose / insulin ratios but significantly higher (95.3%) 
using values  of  either  HOMA or  QUICK I  (Quantitative  insulin  sensitivity 
check index).  According to Negro RS et al., approximately 50% to 70% of all 
women  with  polycystic  ovary  syndrome  have  some  degree  of  insulin 
resistance80. Moreover different studies show that insulin resistance is also seen 
in parents and sisters of women with PCOS81. Although uncertainty exist early 
detection and treatment of insulin resistance in this population could ultimately 
reduce  the  incidence  or  severity  of  diabetesmellitus,  dysplipidemia, 
hypertension and cardiovascular disease80.
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AIM OF THE STUDY
On having reviewed about PCOS, insulin resistance and the prevalence 
of the latter in PCOS which leads to hyperinsulinemia and hyperandrogenism 
the present study was taken up with the view of finding out how many subjects 
with PCOS had insulin resistance. To determine this the following work was 
undertaken in apparently normal subjects and those with PCOS.
1. Determination of the level of fasting plasma glucose and fasting 
plasma insulin.
2. Calculation  of  plasma  glucose  insulin  ratio  and  homeostasis 
model assessment - IR.
3. Determination of the percentage of PCOS women with insulin 
resistance.
4. Determination of lipid parameters as hyperlipidemia is one the 
complication of PCOS.
5. Correlation  of  plasma  insulin  to  plasma  glucose  and  lipid 
parameters.
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MATERIALS AND METHODS
The study was done during the period Jan-2006 to April 2006. It was 
carried out in 2 groups namely control and PCOS subjects in the reproductive 
age group (20 - 40 yrs).
Control Group
The  group  comprised  of  30  apparently  healthy  female  subjects  with 
regular  menstrual  cycle.  They were  selected  from the  staff  of  biochemistry 
department Madras Medical College, Chennai and females who accompanied 
the  patients  attending  endocrinology  outpatient  department  (OPD)  at  the 
Institute of Obstetrics and Gynaecology, Egmore, Chennai.
Test Group
This group comprised females with PCOS who had history of menstrual 
irregularities  /  infertility  and were  attending  the  endocrinology OPD of  the 
Institute  of  Obstetrics  and  Gynaecology,  Egmore,  Chennai.  Based  on  the 
following inclusion and exclusion criteria females of this group were selected.
Inclusion Criteria
1. Patients  with recently  confirmed diagnosis  of polycystic  ovary 
syndrome based on history and clinical examination of abdomen 
and pelvis.
2. Ultra sound finding of unilateral/bilateral polycystic ovaries.
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3. Normal TSH and prolactin levels indicating normal functioning 
of  thyroid and pituitary.
4. Subject of any BMI.
Exclusion Criteria
1. Patients with confirmed diagnosis of PCOS who were already on 
treatment  with  insulin  sensitizing  medications  or  gonadotropin 
releasing hormone (GnRH) agonists like clomiphene citrate.
2. Patients  with  PCOS who had undergone  any form of  surgical 
procedure for infertility.
3. Patients with PCOS and associated diabetes mellitus.
4. Patients with PCOS and associated features of hypothyroidism as 
evidenced by TSH values.
5. Patients with adrenal or ovarian tumors.
Sample Collection
For all the 88 subjects of the study 6ml of peripheral venous blood was 
withdrawn under  sterile  conditions  with  disposable  syringes  after  overnight 
fasting. One ml of blood was transferred into the test tube containing a pinch of 
potassium  oxalate  and  sodium  fluoride  (3:1  mixture)  for  plasma  glucose 
estimation.  In  to  the  other  plain  tube  without  any  anticoagulant  5ml  of 
remaining  blood  was  transferred.  The  seperated  serum  from  this  tube  was 
pipetted into a centrifuge tube and was centrifuged at  2500 revolutions per 
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minute for  five minutes,  to get  clear serum without any cells.  0.5ml of the 
above  serum  was  transferred  into  an  ependroff  and  stored  at  -70o for  the 
estimation of serum insulin.  From the remaining serum, triglycerides (TGL) 
total  cholesterol  (TC) and high density lipoprotein cholesterol  (HDLc) were 
measured  within  6  hours  of  blood  collection  by  enzymatic  methods  using 
commercial kits.
The biochemical parameters undertaken for the study were determined 
using the following methodologies.
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ESTIMATION OF  PLASMA GLUCOSE
Method : Glucose oxidase peroxidase (GOD/POD) 
Kit used : Autopak of Bayer Diagnostics
Principle
Glucose  
oxidase
Glucose + O2 Gluconicacid + H2O2
H2O2 + Phenolic compound   Peroxidase      pink coloured    compound  +2H2O
+4 aminoantipyrine      (Quinonemine)
The  intensity  of  pink  coloured  compound  is  proportional  to  glucose 
concentration and was measured  at 505nm.
Reagents
1. Glucose  reagent  -  consist  of  Glucose  oxidase,  peroxidase,  4-
Aminoantipyrine , 4- hydroxy benzoic acid and phosphate buffer.
2. Glucose standard - 100mg / dl
Sample :  Clear plasma
Reagent Reconstitution
Working  solution  was  prepared  by  dissolving  one  tablet  of  glucose 
reagent in 20ml of deionised water with continuous stirring. It was stored in 
brown bottle.
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Procedure
Reconstituted reagent was brought to room temperature prior to use.
Assay Parameters
Reaction Type : End Point
Reaction slope : Increasing
Wavelength : 505nm (490 - 530)
Incubation time : 15 min at 37oC
Sample volume : 10µl
Reagent volume : 1.0 ml
Zero setting : Reagent blank.
To one ml of working solution 10µl of plasma was added and incubated 
at 37oc for 15 minutes and absorbance was measured at 505nm.
Reference range 
Fasting plasma glucose - 70-100 mg/dl.
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ESTIMATION OF INSULIN
Method : Insulin was estimated by ELISA method using active Insulin 
ELISA kit of Diagnostic System Laboratories.
Principle
This is an "One - step" sandwich type enzyme immunoassay in which 
the  antigen  is  sandwiched  between  two  antibodies.  The  assay  standards  / 
controls  /  and  unkown  serum  samples  were  incubated  with  a  horseradish 
peroxidase (HRP) - labelled anti insulin antibody  in microtitration wells which 
had been coated with another anti - insulin antibody so that antibody - antigen 
antibody complex was formed.  After incubation and washing of excess,  the 
wells  were  incubated  with  the  substrate,  tetramethyl  benzidine  (TMB).  An 
acidic stop solution is then added and the degree of enzymatic turnover of the 
substrate was determined by dual wave length absorbance at 450 and 620 nm.
Reagents
1. Anti - insulin - coated micro titration-strip
One strip  holder  contains  96 polystyrene microtitre  wells  with anti  - 
insulin antibody immobilized to the inside wall of each well.
2. Insulin standards : (Lyophilized).
Vials containing different concentration of standards like 0, 3.0, 10.0, 
50.0,  100; 300 µu/ml. Insulin in human serum with a non -  mercury 
perservative. Standards were reconstituted with 0.5 ml deionized water.
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3. Insulin controls : (Lyophilized) 
2vials containing low and high concetration of insulin in human serum 
with a non - mercury preservative. Reconstitution of each vial done with 
0.5 ml of deionized water.
4. Insulin antibody - enzyme conjugate concentrate  : 
One vial containing anti - insulin antibody conjugated to horse radish 
peroxidase in buffer with a non - mercury preservative.
5. Assay buffer:
Contains protein based buffer.
6. TMB chromogen solution :
One vial containing a solution of tetramethylbenzidine (TMB) in citrate 
buffer with hydrogen peroxide.
7. Wash concentrate :
Contains buffered saline with a non ionic detergent. 
8. Stopping solution : 
0.2 M sulfuric acid.
Specimen : Clear fasting serum.
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Procedure
All specimens and reagents of the kit are brought to room temperature 
(25°C). The reagents and samples were thoroughly mixed before use by gentle 
inversion.  25 µl  of  standards  /  controls  and samples  were  pipetted into the 
appropriate wells. 100 µl of antibody enzyme conjugate solution was added 
into each well and was incubated in a rotar shaker at fast speed (500 - 700 
rpm). Then each well was aspirated and washed 5 times with wash solution. 
Then the plates were dried by blotting. 100 µl of TMB chromogenic substrate 
was added into each well and incubated at fast speed in rotar shaker at (500 - 
700) rpm for 10 minutes at room temperature. Then 100 µl of stop solution was 
added to each well.  The absorbance was read immediately at  450 nm.  The 
absorbance of standards  / controls are plotted with concentration in X axis and 
optical density in Y axis. With the standard curve the concentration of samples 
were found out. 
Reference range
Fasting insulin (Adult) 2.1 - 30.8 µu/ml.
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ESTIMATION OF SERUM TRIGLYCERIDE
Method
Enzymatic colorimetric method
Kit used
Autopak of Bayer Diagnostics
Principle
   Lipoprotein lipase
Triglycerides + H2O    Glycerol + Fatty Acid
   Glycerol kinase
Glycerol + ATP Glycerol-3-Phosphate+ADP
           GPO
Glycerol-3-Phosphate+O2     Dihydroxyacetone Phosphate+H2O2
    Peroxidase 
2H2O2+4-Aminoantipyrine+ADPS      Red quinone+2H2O
GPO = Glycerol - 3- Phosphate Oxidase
ADPS = N-Ethyl-N-Sulfopropyl-n-anisidine
The intensity of purple coloured complex formed during the reaction is 
directly  proportional  to  the  triglycerides  concentration in  the  sample  and is 
measured at 546 nm.
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Reagents
Reagent 1 (Enzymes / Chromogen) :
Lipoprotein lipase > 1100 U/L
Glycerol kinase > 800 U/L
Glycerol-3-Phosphate Oxidase > 5000 U/L
Peroxidase > 350 U/L
4-Aminoantipyrine 0.7 mmol/L
ATP 0.3 mmol/L
Reagent 1A (Buffer) :
Pipes buffer, pH 7.50 50 mmol/L
ADPS 1 mmol / L
Magnesium salt 15 mmol/L
Standard (Triglycerides 200 mg/dL):
Glycerol (Trig. equivalent) 2 g/L
Reagent Reconstitution
Reagents were brought to room temperature. Contents of one bottle of 
reagent 1 was dissolved with one bottle of reagent 1A. It was mixed gently by 
swirling.
Procedure
The  samples  and  the  reconstituted  reagent  were  brought  to  room 
temperature prior to use. The following general system parameters were used to 
with this kit :
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General System Parameters
Reaction Type : Endpoint
Reaction Slope : Increasing
Wavelength : 546 nm (520 - 570)
Flowcell temp. : 30°C
Incubation : 5 min at 37°C
Sample vol. : 10 µl
Reagent vol. : 1.0 ml
Std. concentration : 200 mg/dl
Zero setting with : Reagent Blank
In the test tube following was dispensed
Blank Standard Test
Reconstituted Reagent 1 ml 1 ml 1 ml
Standard - 10 µl -
Sample - - 10 µl
Reading was taken after 5 minutes incubation at 37°C.
Reference Values
Males : 60 - 165 mg/dl
Females : 40 - 140 mg/dl
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ESTIMATION OF SERUM TOTAL CHOLESTEROL
Method
Cholesterol Esterease - Cholesterol Oxidase
Kit used
Autospan of  Span Diagnostics Ltd
Principle
Cholesterol
Esterease
Cholesterol Ester + H2O Cholesterol + Fatty Acids
Cholesterol
Oxidase
Cholesterol  + O2            Cholestenone + H2O2
2H2O2 + Phenol + 4-Aminoantipyrine Peroxidase   Red quinone + 4-H2O
The concentration of cholesterol in the sample is directly proportional to 
the intensity of the red complex (Red Quinone) which is measured at 500 nm.
Reagents
Reagent 1 (Enzymes / Chromogen)
Cholesterol esterase - ≥ 200 U/L
Cholesterol oxidase - ≥ 250 U/L
Peroxidase - ≥ 1000 U/L
4-Aminoantipyrine - 0.5 mmol/L
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Reagent 1A (Buffer)
Pipes buffer, pH 6.90 - 50 mmol/L
Phenol - 25 mmol/L
Sodium Cholate - 0.5 mmol/L
Standard (Cholesterol 200 mg/dL)
Cholesterol - 2 g/L
Reagent Reconstitution
Reagents were brought to the room temperature contents of one bottle of 
reagent 1 was dissolved with one bottle of reagent 1A. It was mixed by gentle 
swirling.
Procedure
The  samples  and  the  reconstituted  reagent  were  brought  to  room 
temperature prior to use.
Instrument was set using following system parameters
General System Parameters
Reaction type : Endpoint
Reaction slope : Increasing
Wavelength : 500 nm (492 - 550)
Flowcell temp. : 30°C
Incubation : 5 min at 37°C
Sample vol. : 10 µl
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Reagent vol. : 1.0 ml
Std. concentration : 200 mg/dl
Zero setting with : Reagent Blank
In the tube following was dispensed :
Blank Standard Test
Reconstituted Reagent 1 ml 1 ml 1 ml
Standard - 10 µl -
Sample - - 10 µl
Reading was taken after 5 minutes incubation at 37°C.
Reference Values
Cholesterol: Serum / Plasma: 150 - 260 mg/dl
Normal  cholesterol  level  is  affected  by  stress,  age,  pregnancy  and 
hormonal balance.
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ESTIMATION OF HDL - CHOLESTEROL
Method
Posphotungstate method
Kit used
Autopak of Bayer Diagnostics
Principle
Chylomicrons,  VLDL  (Very  low  density  lipopproteins)  and  LDL 
fractions in serum or plasma are separated from HDL by precipitating with 
phosphotungstic  acid  and  magnesium  chloride.  After  centrifugation,  the 
cholesterol in the HDL fraction, which remains in the supernatant is assayed 
with  enzymatic  cholesterol  method,  using  cholesterol  esterase,  cholesterol 
oxidase, peroxidase and the chromogen 4-aminoantipyrine / Phenol.
Reagents
Reagent 1 (Enzymes / Chromogen) :
Cholesterol esterase > 200 U/L
Cholesterol oxidase > 250 U/L
Peroxidase > 1000 U/L
4-Aminoantipyrine 0.5 mmol/L
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Reagent 1A (Buffer) :
Pipes buffer, pH 6.90 50 mmol/L
Phenol 24 mmol / L
Sodium Cholate 0.5 mmol/L
Reagent 2 (Precipitating Reagent) :
Phosphotungstic Acid 2.4 mmol/L
Magnesium Chloride 39 mmol/L
Standard (HDL Cholesterol 50 mg/dL) :
Cholesterol 0.5 g/L
Reagent Reconstitution
Reagents were brought to room temperature. Contents of one bottle of 
reagent 1 was dissolved with one bottle of reagent 1A. It was mixed gently by 
swirling.
Procedure
1. Precipitation
Following was dispensed into centrifuge Tubes :
Test
Sample 0.20 ml (200 µl)
Precipitating Reagent 2 0.20 ml (200 µl)
Mixed Well
It was centrifuged at 1500 g or 3500 - 4000 rpm for 10 minutes.
Clear  supernatant  was  immediately  separated  and  cholesterol  content 
was determined as follows :
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II CHOLESTEROL ASSAY
The following general system parameters was used with this kit :
General System Parameters
Reaction type : Endpoint
Reaction slope : Increasing
Wavelength : 500 nm (492 - 550 nm)
Flowcell temp. : 30°C
Incubation : 5 min at 37°C
Sample vol. : 20 µl
Reagent vol. : 1.0 ml
Std. concentration : 100 mg/dl
Zero setting with : Reagent blank
In the test tube following was dispensed
Blank Standard Test
Reconstituted Reagent 1 ml 1 ml 1 ml
Standard - 20 µl -
Supernatant - - 20 µl
Reading was taken after 5 minutes of incubation at 37°C.
Reference Values
Serum / Plasma HDLc : 30 - 70 mg/dl
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VLDL AND LDL CHOLESTEROL
These parameters were calculated using Friedwald's formula which is 
given below.
LDL c = TC - (HDL c + VLDL c)
VLDLc = TGL / 5
Glucose insulin ratio is arrived directly from Glucose and Insulin levels 
from the formula G/I.
HOMA - IR - This is arrived at using the following formula.
HOMA - IR = [(Glucose in mg / dl x 0.05551) x Insulin in µu/ml)].
     22.5
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RESULTS
The  estimated  levels  of  fasting  serum insulin  and  other  biochemical 
parameters  namely  fasting  plasma  glucose,  serum  triglycerides,  total 
cholesterol, high density lipoprotein cholesterol and the calculated parameters, 
very low density lipoprotein cholesterol of all the subjects selected for study 
irrespective of the grouping are tabulated in master Table No.I, along with the 
calculated  Glucose  Insulin  ratio  and Homeostasis  model  assessment  insulin 
resistance (HOMA - IR) which are the indices of Insulin resistance.  Of the 
selected  subjects  serial  No.1-30  in  the  above  table  consists  of  the  control 
subjects and serial No.31-88 consists of patients with PCOS.
Table No.II gives the levels of blood parameters in apparently normal 
women (i.e serial. No.1-30 of the master table I) who form the control group 
while  table  No.III  represents  the  same  in  women  with  PCOS  (i.e  serial 
No.31-88 of master table I). The mean level of each parameter along with its 
standard deviation (S.D.) is also shown in the above 2 tables namely table II 
and III. The mean levels of each blood parameter in the two groups are also 
shown as bar diagram in fig.No.6 to 8.
To determine how far  the levels  of blood parameters  varied in the 2 
groups the mean levels in table III are compared with that of table II in table 
IV.  The  statistical  significance  for  the  variation  in  the  levels  of  the  blood 
parameters  between the  2  groups  is  determined  from the  p  value  which  is 
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arrived at using the student's 't'  test.
The correlation of plasma insulin to fasting plasmaglucose (FPG) and 
the lipid parameters are shown in table V. The correlation have been arrived at 
using  Karl  Pearson's  correlation  coefficient.  The  above  correlation  is  also 
depicted in scatter diagrams from Fig.No.9 to 16.
54
DISCUSSION
The  validity  of  the  mean  values  obtained  for  the  analysed  blood 
parameters in apparently normal women to be used as reference range for the 
study is first scrutinised.
The  mean  value  of  82.37  ±  7.09  mg/dl  obtained  for  fasting  plasma 
glucose  is  well  within  the  reference  range  of  70  -  100  mg /  dl  of  the  kit 
methodology adopted for its determination. Moreover the value is well within 
that quoted in standard text books for fasting plasma glucose82. 
The value of 24.87 ± 16.38 µu/ml obtained for fasting insulin is found to 
be at the higher end of 2 - 25 µu/ml quoted by carl.  A Burits82. The higher 
reference  range  obtained  can  probably  be  attributed  to  the  fact  that  obese 
individuals have not been excluded in the control group; it is a well known fact 
that  obesity  is  associated  with  insulin  resistance  which  can  lead  to 
hyperinsulinemia38,42. Moreover it can also be due to the different race of the 
subjects analysed in this study compared to carl. A Burtis who arrived at from 
western population. However it coincides much better with the reference range 
of 2.1 to 30.8 given in the kit methodology adopted for its analysis Similarly 
the mean levels of the lipid parameters are well within the reference range of 
their  respective  methodologies  and that  of  standard  text  books82.  Hence the 
acceptance of the mean levels of the analysed biochemical parameters namely 
82.37  ±  7.09  for  fasting  plasma  glucose,  24.87  ±  16.38  for  fasting  serum 
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insulin, 103.70 ± 29.31 for serum TGL, 164.27 ± 26.99 for total cholesterol, 
46.71  ±  9.44  for  HDL  c  obtained  from  apparently  normal  women  as  the 
reference  range  for  the  study  is  valid.  Therefore  levels  of  the  calculated 
parameters obtained from the above values namely 23.11 ± 14.34 for VLDL c, 
93.02 ± 26.43 for LDL c, 6.13 ± 5.96 for glucose insulin ratio and 5.09 ± 3.43 
for the HOMA - IR are acceptable. 
On  scrutinising  Table  IV where  the  mean  levels  of  the  biochemical 
parameters are compared with the reference range obtained in the study it is 
found that among the analysed parameters insulin, TGL and total cholesterol 
have increased  from  that  of  the level in controls to highly significant levels 
(P = .003 for insulin,  .001 for TGL and TC). On the other hand HDL c is 
found to be significantly lowered (p = .02). Among the calculated parameters 
HOMA - IR, VLDL c and LDL c are increased to highly significant levels (p 
= .003 for HOMA - IR, .004 for VLDL C and .001 for LDL c), while the G/I is 
decreased significantly (p - .04).
Fasting  plasma insulin  which shows a  highly  significant  elevation in 
PCOS from the control level is attributed to the insulin resistance as it has been 
well established that there is a strong association between PCOS and insulin 
resistance  which  will  lead  to  impaired  glucose  tolerance  and compensatory 
hyperinsulinemia  which  is  the  most  significant  metabolic  abnormality  in 
PCOS46,47,84-88. In the study the plasma insulin the most significant abnormality 
of PCOS has increased to highly significant levels but plasma glucose does not 
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show any statistical elevation contrary to the finding of Dunaiff A.
The state of insulin  resistance in PCOS as reviewed though not well 
understood, can be due to :
1. Peripheral target tissue resistance to insulin which can be the result of 
auto  antibodies  to  insulin  receptors  leading  to  decrease  in  insulin 
binding;  post  receptor  defects  such  as  abnormal  pattern  of 
phosphorylation of serine and  tyrosine residues of insulin receptors and 
a decrease in insulin receptor sites in target tissues.
2. Decreased  hepatic  clearance  of  insulin  due  to  decreased  hepatic 
extraction.
Careful  scrutiny  of  the  levels  of  insulin  in  the  58  PCOS  subjects 
revealed that 42 of them have mild to moderate elevation as per the criteria of 
C.Ronal Kaln et al., the remaining 16 had levels within reference range. This 
coincides with the finding of catherin Marin Deugarte et al., who have stated 
that though insulin resistance is a common abnormality in PCOS it is not an 
universal feature78.
The abscence of any significance for glucose in PCOS inspite of insulin 
resistance is attributed to the prevention of plasma glucose elevation by the 
compensatory hyper insulinemia which is a consequence of insulin resistance. 
This fact has been also emphasised by Serdar E. Bulun et al., who have stated 
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that  in  PCOS  subjects  with  insulin  resistance  normal  glucose  level  is 
maintained  at  the  expense  of  increased  circulating  insulin  to  overcome the 
underlying defect59.
Assessment  of  the  2  parameters  arrived  at  from plasma  glucose  and 
insulin levels reveal the following. The ratio derived from the above plasma 
glucose and insulin is found to be significantly reduced in PCOS (p = .04). This 
is only natural because out of the 2 parameters involved in the calculation of 
the ratio the numerator glucose level has not changed statistically while the 
denominator insulin level has increased to highly significant levels in PCOS. 
HOMA - IR is increased to highly significant level in PCOS (p .003) 
because it is arrived at using the formula.
glucose in mg/dl x 0.05551 x insulin in µu/ml
_      ________________________________________
22.5
Even  though  plasma  glucose  level  does  not  show  any  significant 
elevation insulin is increased to highly significant levels which increases the 
HOMA - IR to a highly significant levels in PCOS.
As the above 2 parameters namely glucose insulin ratio and HOMA - IR 
indicate insulin resistance careful scrutiny of their levels indicate the following. 
The levels of glucose insulin ratio when analysed keeping in mind the criteria 
of Marilyn R. Richard15 that levels of glucose insulin ratio of more than 4.5 
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HOMA - IR =
excludes insulin resistance and less than that indicate insulin resistance it is 
observed that 46 PCOS subjects in this study have values less than 4.5 while 
the remaining 12 have values higher to it. Hence as per the above values 79.3% 
of PCOS subjects have insulin resistance in this study which is higher to the 
percentage arrived by carmina E et al., which is 65.479. This difference in the 
percentage  of  insulin  resistance  in  PCOS  can  be  attributed  to  the  racial 
difference of the subjects analysed in this study from that of the former study 
by carmina E et al., as genetic predisposition has also been identified as one of 
the  etiological  causes  for  the  syndrome48.  Moreover  even in  controls  group 
where the mean is  6.13,  15 out of 30 subjects  have G/I ratio  less  than 4.5 
indicating that 50% of the controls selected have insulin resistance which has 
led to hyperinsulinemia in these subjects. The lower glucose insulin ratio in 
some control subjects can be attributed to the obesity of these individuals who 
have been selected in the control group as it has been reviewed that insulin 
resistance is associated with obesity38,39,40.
HOMA - IR levels scrutiny based on the statement of Dr.Elizabeth G. 
Nabel  who  had  found  that  HOMA  -  IR  more  than  3.8  indicates  insulin 
resistance it is observed that 46 PCOS subjects have HOMA - IR levels more 
than 3.8 assuring that 79.3% of subjects with PCOS have insulin resistance 
which is similar finding to that obtained from G/I ratio.  But when mean of 
HOMA - IR in controls of the study is observed it is found that it is 5.09 ± 3.34 
which is also greater to the above cut off level of 3.8. Therefore it is inferred 
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that  certain  subjects  in  the  control  group  of  this  study  have  also  insulin 
resistance  which  leads  to  hyperinsulinemia  and  therefore  has  raised  the 
reference range of  insulin in  the control  group higher to that  quoted in the 
standard text books82. In this study fifteen subjects of the control group have 
HOMA - IR greater than 3.8 indicating as in glucose insulin ratio that 50% of 
the  control  selected  have  insulin  resistance  which  correlates  with  obese 
subjects. 
Among the lipid parameters, TGL, TC, VLDLc and LDLc show a highly 
significant elevation from the level in controls, while HDLc shows a significant 
decrease. It is well documented fact that insulin resistance in PCOS can cause 
alteration in lipid metabolism59. Hence the elevation of lipid parameters can be 
the result of dyslipidemia which in one of the complication in PCOS.
The various causes pertaining to the increased levels of the above lipid 
parameters are enumerated below.
1. Hyperinsulinemia is known to enhance hepatic very low density 
lipoprotein synthesis and thus can directly contribute to increased 
plasma TGL.
2. As the insulin resistance restricts the action of lipoprotein lipase 
more of adipose tissue TGL is hydrolysed leading to increase in 
free  fatty  acids  which  inturn  will  elevate  TGL  synthesis  → 
VLDL production → LDL production.
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The significant decrease  in  HDL-c in PCOS can be attributed to  the 
increased rate of HDL degradation which can exceed the rate of its synthesis.
When  the  plasma  insulin  levels  are  correlated  with  fasting  plasma 
glucose and lipid parameters the following are revealed from the table No.V 
and is also in evident in scatter diagram in Fig.No.9 to 16.
1. Fasting plasma insulin with fasting plasma glucose shows poor 
correlation in both control as well as the PCO's group.
2. Fasting  plasma  insulin  with  TGL  and  TC  shows  in  poor 
correlation in controls and a fair positive correlation in PCOS.
3. Fasting plasma insulin with HDL-c shows a poor correlation in 
controls and a  fair correlation in PCOS.
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CONCLUSION
From the discussion held sofar on the results obtained in the study on 
PCOS  the  following  conclusion  is  arrived  at  regarding  the  biochemical 
parameters.
1. The  plasma  insulin  in  control  in  24.87  ±  16.38  µu/ml  which  is  the 
reference range for the study.
2. Plasma insulin is elevated in PCOS above the reference range indicating 
hyper insulinemia in this group.
3. Glucose insulin ratio and HOMA - IR the marker of insulin resistance 
are decreased and increased from the reference range respectively.
4. Analysis  of  glucose  insulin  ratio  and  HOMA reveals  that  79.3%  of 
PCOS are insulin resistant. 
5. Correlation of insulin with plasma glucose is poor in both control and 
PCOS.  Correlation of insulin with TGL and TC and HDLc are poor in 
control  but  has  fair  positive  correlation  with  TGL and  TC  and  fair 
negative correlation with HDLc in PCOS.
6. 50% of subjects in the control group have insulin resistance.
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SCOPE FOR FURTHER STUDY
1. Insulin resistance can be studied in obese and non obese controls and 
PCOS.
2. Insulin  resistance  can  be  studied  in  other  family  members  of  these 
patients.
3. Study of levels of insulin and glucose simultaneously by oral glucose 
tolerance test in PCOS.
4. Insulin resistance can be analysed along with sex hormones.
5. Levels of leptin, adiponectin can be studied in PCOS patients.
6. Study of levels of plasminogen activator inhibitor in these patients.
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ABBREVIATIONS
PCOS - Polycystic ovary syndrome
LH - Luteinizing hormone
FSH - Follicular stimulating hormone
USG - Ultrasonography
TSH - Thyroid stimulating hormone
DHEAS - Dehydroepiandrosterone sulfate
FFA - Free fatty acids
TNFα - Tumor necrosis factor
IRS-I - Insulin receptor substrate - I
GTT - Glucose tolerance test
GI ratio - Glucose insulin ratio
HOMA - IR - Homeostatic model assessment insulin 
resistance
TGL - Triglycerids
HDLc - High density lipoprotein - cholesterol
GnRH - Gonadotropin releasing hormone
QUICKI - Quantitative insulin sensitivity check index
BMI - Body mass index
ELISA - Enzyme linked immunosorbent assay
HRP - Horse radish peroxidase
TMB - Tetramethyl benzidine
FPG - Fasting plasma glucose
LDLc - Low density lipo protein
VLDLc - Very low density lipo protein
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